Skip to main content

News Center

Company Announcement

Previous Pause Next

Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review

Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review

Highlights progress and commitment to deliver breakthrough medicines to meet the needs of patients around the world Plans to maximize potential of...

[Media Report] Serving In the Name of Progress

[Media Report] Serving In the Name of Progress

(Joaquin Duato, executive vice-president and worldwide chairman of pharmaceuticals at Johnson & Johnson) A senior executive at...

China Food and Drug Administration approves IMBRUVICA® (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs

China Food and Drug Administration approves IMBRUVICA® (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs

[Beijing], [30 August, 2017] – Xian Janssen Pharmaceutical Ltd. announced today that the China Food and Drug Administration (CFDA) has approved IMBRUVIC...

Follow us on WeChat

Corporate News

2019/05/16

Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review

2018/03/27

Janssen joins partnership in China to provide access to SIRTURO® (bedaquiline) for the treatment of multidrug-resistant tuberculosis (MDR-TB)

2018/01/23

IMBRUVICA and REMICADE included on the Zhejiang Province Reimbursement List for Drugs Treating Major Illnesses

2017/11/13

XIAN JANSSEN LAUNCHES EARLY IMBRUVICA® (IBRUTINIB)

2017/09/25

【ChinaDaily】Serving in the name of progress

2017/09/21

Xian Janssen and Shaanxi Province Forestry Department Announce a New Phase of Collaboration to Protect Giant Pandas

2017/07/19

Xian Janssen: VELCADE® and ZYTIGA® Included on the NRDL 2017

2017/05/19

Johnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical Business Review Meeting